{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:57:48Z","timestamp":1790834268327,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":111,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fujian Provincial Natural Science Foundation of China","award":["2022J011416"],"award-info":[{"award-number":["2022J011416"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16335-1","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:34:52Z","timestamp":1781246092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical evaluation of a fluorinated bifendate derivative in triple-negative breast cancer: integrated in vitro and in vivo evidence of antitumor activity"],"prefix":"10.1186","volume":"26","author":[{"given":"Lisa Zongyong","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Qiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"1","key":"16335_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"16335_CR2","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T S\u00f8rlie","year":"2001","unstructured":"S\u00f8rlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van De Rijn M, Jeffrey SS. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"16335_CR3","doi-asserted-by":"publisher","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T S\u00f8rlie","year":"2003","unstructured":"S\u00f8rlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"16335_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288\u2013300.","journal-title":"JAMA"},{"issue":"25","key":"16335_CR5","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.2217\/fon-2018-0131","volume":"14","author":"N Tray","year":"2018","unstructured":"Tray N, Adams S, Esteva FJ. Antibody\u2013drug conjugates in triple negative breast cancer. Future Oncol. 2018;14(25):2651\u201361.","journal-title":"Future Oncol"},{"issue":"12","key":"16335_CR6","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.tips.2015.08.009","volume":"36","author":"M Kalimutho","year":"2015","unstructured":"Kalimutho M, Parsons K, Mittal D, L\u00f3pez JA, Srihari S, Khanna KK. Targeted therapies for triple-negative breast cancer: combating a stubborn disease. Trends Pharmacol Sci. 2015;36(12):822\u201346.","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"16335_CR7","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.3390\/jcm11092331","volume":"11","author":"R Nishimura","year":"2022","unstructured":"Nishimura R, Osako T, Okumura Y, Nakano M, Otsuka H, Fujisue M, Arima N. Triple negative breast cancer: an analysis of the subtypes and the effects of menopausal status on invasive breast cancer. J Clin Med. 2022;11(9):2331.","journal-title":"J Clin Med"},{"issue":"11","key":"16335_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"16335_CR9","doi-asserted-by":"publisher","first-page":"109157","DOI":"10.1016\/j.bioorg.2025.109157","volume":"166","author":"SY Ewieda","year":"2025","unstructured":"Ewieda SY, Ahmed EM, Gohar NA, Ibrahim SG, Essa MA, Nemr MTM. Design, synthesis, and antitumor evaluation of new pyridazinone scaffolds as dual EGFR\/VEGFR-2 kinase inhibitors and apoptotic cells inducers. Bioorg Chem. 2025;166:109157.","journal-title":"Bioorg Chem"},{"key":"16335_CR10","doi-asserted-by":"publisher","first-page":"109486","DOI":"10.1016\/j.bioorg.2026.109486","volume":"170","author":"SY Ewieda","year":"2026","unstructured":"Ewieda SY, Ahmed EM, Halim PA, Ibrahim SG, Gouda KM, Abdalla M, Eltayb WA, Nemr MTM. Discovery of novel pyridazinone derivatives as EGFRWT\/ EGFRT790M kinase inhibitors; design, synthesis, antitumor evaluation, and molecular dynamic simulations. Bioorg Chem. 2026;170:109486.","journal-title":"Bioorg Chem"},{"issue":"1","key":"16335_CR11","doi-asserted-by":"publisher","first-page":"2281262","DOI":"10.1080\/14756366.2023.2281262","volume":"38","author":"WAA Fadaly","year":"2023","unstructured":"Fadaly WAA, Zidan TH, Kahk NM, Mohamed FEA, Abdelhakeem MM, Khalil RG, Nemr MTM. New pyrazolyl-thiazolidinone\/thiazole derivatives as celecoxib\/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory\/anti-proliferative activities, apoptosis, molecular modelling and ADME studies. J Enzyme Inhib Med Chem. 2023;38(1):2281262.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"8","key":"16335_CR12","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329\u201334.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"16335_CR13","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2007.14.4287","volume":"26","author":"PL Nguyen","year":"2008","unstructured":"Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26(14):2373\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"16335_CR14","first-page":"2","volume":"1","author":"C Wang","year":"2008","unstructured":"Wang C, Xu YQ. Diphenyl dimethyl bicarboxylate in the treatment of viral hepatitis, adjuvant or curative? Gastroenterol Res. 2008;1(1):2.","journal-title":"Gastroenterol Res"},{"issue":"1","key":"16335_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s10330-007-0076-6","volume":"7","author":"H Sun","year":"2008","unstructured":"Sun H, Liu G. The study of anti-hepatitis drug dimethyl dicarboxylate biphenyl on invasion of human hepatocellular carcinoma MHCC97-H cells and its active mechanisms. Chin Ger J Clin Oncol. 2008;7(1):2\u20136.","journal-title":"Chin Ger J Clin Oncol"},{"issue":"12","key":"16335_CR16","first-page":"1464","volume":"25","author":"H Sun","year":"2006","unstructured":"Sun H, Liu G-T. Inhibitory effect of dimethyl dicarboxylate biphenyl on invasion of human hepatocellular carcinoma cell line MHCC97-H with high metastasis potential and its mechanisms. Chin J Cancer. 2006;25(12):1464\u20139.","journal-title":"Chin J Cancer"},{"issue":"8","key":"16335_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jfluchem.2006.06.007","volume":"127","author":"KL Kirk","year":"2006","unstructured":"Kirk KL. Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules. J Fluor Chem. 2006;127(8):1013\u201329.","journal-title":"J Fluor Chem"},{"issue":"21","key":"16335_CR18","doi-asserted-by":"publisher","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","volume":"58","author":"EP Gillis","year":"2015","unstructured":"Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA. Applications of fluorine in medicinal chemistry. J Med Chem. 2015;58(21):8315\u201359.","journal-title":"J Med Chem"},{"issue":"1","key":"16335_CR19","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s12672-025-02545-9","volume":"16","author":"H-y Huang","year":"2025","unstructured":"Huang H-y, Lin LZY, Lu X-y, Jiang Y. F-\u03b1-DDB-derivative, a novel synthetic of bifendate, plus epirubicin improves antitumor efficacy against triple negative breast cancer without additional cardiotoxicity. Discover Oncol. 2025;16(1):690.","journal-title":"Discover Oncol"},{"issue":"1","key":"16335_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40779-021-00358-9","volume":"8","author":"D-D Zhou","year":"2021","unstructured":"Zhou D-D, Bai W-Q, Zhai X-T, Sun L-P, Zhen Y-S, Li Z-R, Miao Q-F. Excellent effects and possible mechanisms of action of a new antibody\u2013drug conjugate against EGFR-positive triple-negative breast cancer. Military Med Res. 2021;8(1):63.","journal-title":"Military Med Res"},{"issue":"null","key":"16335_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/DDDT.S398887","volume":"17","author":"S Gao","year":"2023","unstructured":"Gao S, Zhang X, Liu J, Ji F, Zhang Z, Meng Q, Zhang Q, Han X, Wu H, Yin Y, Lv Y, Shi W. Icariin induces triple-negative breast cancer cell apoptosis and suppresses invasion by inhibiting the JNK\/c-Jun signaling pathway. Drug Des Devel Ther. 2023;17(null):821\u201336.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"16335_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3892\/ol.2020.11608","volume":"20","author":"H Wang","year":"2020","unstructured":"Wang H, Zhao L, Wu J, Hong J, Wang S. Propofol induces ROS\u2013mediated intrinsic apoptosis and migration in triple\u2013negative breast cancer cells. Oncol Lett. 2020;20(1):810\u20136.","journal-title":"Oncol Lett"},{"issue":"17","key":"16335_CR23","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.3390\/cancers13174455","volume":"13","author":"MG Davey","year":"2021","unstructured":"Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel). 2021;13(17):4455.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"16335_CR24","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113(7):808\u201319.","journal-title":"J Natl Cancer Inst"},{"key":"16335_CR25","doi-asserted-by":"publisher","first-page":"117822342110169","DOI":"10.1177\/11782234211016977","volume":"15","author":"MA Arafah","year":"2021","unstructured":"Arafah MA, Ouban A, Ameer OZ, Quek KJ. KI-67 LI expression in triple-negative breast cancer patients and its significance. Breast Cancer (Auckl). 2021;15:11782234211016977.","journal-title":"Breast Cancer (Auckl)"},{"key":"16335_CR26","first-page":"100119","volume":"9","author":"U Langeh","year":"2023","unstructured":"Langeh U, Kumar V, Ahuja P, Singh C, Singh A. An update on breast cancer chemotherapy-associated toxicity and their management approaches. Health Sci Rev. 2023;9:100119.","journal-title":"Health Sci Rev"},{"issue":"2","key":"16335_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/biomedicines9020189","volume":"9","author":"T Brown","year":"2021","unstructured":"Brown T, Sykes D, Allen AR. Implications of breast cancer chemotherapy-induced inflammation on the gut, liver, and central nervous system. Biomedicines. 2021;9(2):189.","journal-title":"Biomedicines"},{"key":"16335_CR28","doi-asserted-by":"crossref","unstructured":"Freitas JT, Jozic I, Bedogni B. Wound healing assay for melanoma cell migration. Melanoma: Methods and Protocols: Springer; 2021. p. 65\u201371.","DOI":"10.1007\/978-1-0716-1205-7_4"},{"issue":"1","key":"16335_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40360-018-0284-4","volume":"20","author":"X Wang","year":"2019","unstructured":"Wang X, Decker CC, Zechner L, Krstin S, Wink M. In vitro wound healing of tumor cells: inhibition of cell migration by selected cytotoxic alkaloids. BMC Pharmacol Toxicol. 2019;20(1):4.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"16335_CR30","doi-asserted-by":"publisher","first-page":"e1675","DOI":"10.1038\/cddis.2015.20","volume":"6","author":"V Labi","year":"2015","unstructured":"Labi V, Erlacher M. How cell death shapes cancer. Cell Death Dis. 2015;6(3):e1675\u2013e.","journal-title":"Cell Death Dis"},{"issue":"4","key":"16335_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1039\/c0ib00144a","volume":"3","author":"J Plati","year":"2011","unstructured":"Plati J, Bucur O, Khosravi-Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb). 2011;3(4):279\u201396.","journal-title":"Integr Biol (Camb)"},{"issue":"6","key":"16335_CR32","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1634\/theoncologist.2011-0377","volume":"17","author":"C Bartholomeusz","year":"2012","unstructured":"Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortob\u00e1gyi GN. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist. 2012;17(6):766\u201374.","journal-title":"Oncologist"},{"issue":"13","key":"16335_CR33","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.3390\/cancers17132232","volume":"17","author":"A Hassan","year":"2025","unstructured":"Hassan A, Aubel C. The PI3K\/Akt\/mTOR signaling pathway in triple-negative breast cancer: a resistance pathway and a prime target for targeted therapies. Cancers (Basel). 2025;17(13):2232.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"16335_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","volume":"31","author":"H-p Zhang","year":"2024","unstructured":"Zhang H-p, Jiang R-y, Zhu J-y, Sun K-n, Huang Y, Zhou H-h, Zheng Y-b. Wang X-j. PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast Cancer. 2024;31(4):539\u201351.","journal-title":"Breast Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16335-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16335-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16335-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:08:40Z","timestamp":1790831320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16335-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16335"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16335-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures were approved by the Shanghai Model Organisms Center Institutional Animal Care and Use Committee (SRCMO-IACUC No. 2024-0003) and were performed in accordance with institutional guidelines and regulations. Tumor dimensions were monitored throughout the study using calipers, and no animals exceeded the approved tumor size limits. At the experimental endpoint, mice were anesthetized with isoflurane in oxygen and euthanized by cervical dislocation after confirmation of deep anesthesia and loss of consciousness. Death was confirmed by the absence of corneal reflex and cessation of breathing for more than 1\u00a0min.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1156"}}